Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Betta Pharmaceuticals Co., Ltd.
  6. Summary
    300558   CNE100002DD9

BETTA PHARMACEUTICALS CO., LTD.

(300558)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
11/22/2021 11/23/2021 11/24/2021 11/25/2021 11/26/2021 Date
86.48 87.38 87.42 87.37 87.37 Last
4350072 2240498 1516030 1625280 1401947 Volume
-2.97% +1.04% +0.05% -0.06% 0.00% Change
Estimated financial data (e)
Sales 2021 2 437 M 382 M 382 M
Net income 2021 454 M 71,1 M 71,1 M
Net cash position 2021 1 332 M 209 M 209 M
P/E ratio 2021 80,2x
Yield 2021 0,34%
Sales 2022 3 422 M 536 M 536 M
Net income 2022 735 M 115 M 115 M
Net cash position 2022 1 819 M 285 M 285 M
P/E ratio 2022 60,1x
Yield 2022 0,65%
Capitalization 36 285 M 5 677 M 5 683 M
EV / Sales 2021 14,3x
EV / Sales 2022 10,1x
Nbr of Employees 1 600
Free-Float 48,1%
More Financials
Company
Betta Pharmaceuticals Co., Ltd. is a China-based company principally engaged in the research and development, manufacturing, sales and marketing of drugs to treat malignant tumors, diabetes, cardiovascular and cerebrovascular diseases. The Company’s core product is icotinib, which is a kind of antineoplastic agent. Its products also include burn pain relieving plaster, oryzanol vitamin B1 and vitamin B6 tablets.... 
Sector
Pharmaceuticals
Calendar
04/27Earnings Release
More about the company
Ratings of Betta Pharmaceuticals Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about BETTA PHARMACEUTICALS CO., LTD.
10/27Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended Sept..
CI
09/17Hangzhou Neoantigen Biotechnology co., LTD. announced that it has received $3.1 million..
CI
08/09Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 3..
CI
08/03MARKET CHATTER : JL Mag Rare-Earth Files for $200 Million Hong Kong IPO; Shares Jump 3%
MT
06/22MARKET CHATTER : China Tourism Group to File for Hong Kong IPO This Week
MT
06/08MARKET CHATTER : Chaoju Eye Care Set for Hong Kong Listing Hearing This Week
MT
06/08MARKET CHATTER : China Tourism Group Eyes Secondary Listing in Hong Kong to Raise $10 Bill..
MT
06/06MARKET CHATTER : Chinese Bubble Tea Chain Operator Nayuki Passes Hong Kong Listing Hearing
MT
06/01MARKET CHATTER : Chinese Bubble Tea Chain Operator Nayuki Set for Hong Kong Listing Hearin..
MT
05/25MARKET CHATTER : Betta Pharmaceuticals Set for Hong Kong Listing Hearing This Week
MT
04/28Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended Ma..
CI
04/16Betta Pharmaceuticals Co., Ltd. Approves the Cash Dividend for the Year 2020
CI
03/26Betta Pharmaceuticals Co., Ltd. Announces Profit Distribution Proposal for 2020
CI
03/25Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended Decemb..
CI
2020Zhejiang Betta Pharmaceutical Technology Co., Ltd. agreed to acquire Zhejiang Betta Blu..
CI
More news
News in other languages on BETTA PHARMACEUTICALS CO., LTD.

- No features available -

More news
Chart BETTA PHARMACEUTICALS CO., LTD.
Duration : Period :
Betta Pharmaceuticals Co., Ltd. Technical Analysis Chart | 300558 | CNE100002DD9 | MarketScreener
Technical analysis trends BETTA PHARMACEUTICALS CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 87,37 CNY
Average target price 135,40 CNY
Spread / Average Target 55,0%
EPS Revisions
Managers and Directors
Lie Ming Ding Chairman, Co-Chief Executive Officer & GM
Jia Tong Co-Chief Executive Officer & Director
Jian Xun Fan Chief Financial Officer, Director & Vice President
Yang Nan Zhang Chairman-Supervisory Board
Jiang Wan Chief Operating Officer, Executive Director & SVP
Sector and Competitors